Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT01802203
Official study title

trūFreeze® Spray Cryotherapy Patient Registry

Study summary

To collect efficacy and outcomes data related to the use of trūFreeze® spray cryotherapy for the treatment of unwanted tissue in the pulmonary and gastrointestinal settings.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedtruFreeze Spray Cryotherapy

The study team can explain what participation involves.

Who it may be forBarrett Esophagus · Esophageal Dysplasia

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 25, 2022 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?16 U.S. locations

Locations may change over time.

Who runs it?US Endoscopy Group Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
US Endoscopy Group Inc.
Interventions being studied
Device: truFreeze Spray Cryotherapy
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • 1. GI conditions include:
  • Barrett's Esophagus (BE) with or without dysplasia
  • Squamous dysplasia
  • Esophageal cancer, any stage 2. Pulmonary conditions include:
  • Any endobronchial cancerous or precancerous disease located within the central airways
  • Any non-malignant endobronchial process of the central airways that results in abnormal mucosa (i.e. granulation tissue, papillomatosis, sarcoidosis, tuberculosis, etc.)
  • Tracheal or bronchial stenosis (malignant or benign)
  • Any pleural disease, malignant or benign All subjects are required to be able to provide written informed consent
Reasons someone may not be able to joinExclusion criteria

1. Gastrointestinal

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Scripps Green HosptialLa Jolla, California
  • University of Colorado DenverDenver, Colorado
  • Borland-Groover ClinicJacksonville, Florida
  • Ochsner Medical CenterKenner, Louisiana
  • University of MarylandBaltimore, Maryland
  • Walter Reed National Military Medical CenterBethesda, Maryland
  • Massachusetts General HosptialBoston, Massachusetts
  • Boston University Medical CenterBoston, Massachusetts
  • Beth Israel Deaconess Medical CenterBoston, Massachusetts
  • ProHEALTH Care AssociatesLake Success, New York
  • NYUNew York, New York
  • University of Rochester/Strong Memorial Medical CenterRochester, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 25, 2022. Always confirm current availability with the study team.

View original record ↗